Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Luvixasertib by Treadwell Therapeutics for Colorectal Cancer: Likelihood of Approval
Luvixasertib is under clinical development by Treadwell Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
Luvixasertib by Treadwell Therapeutics for Pancreatic Cancer: Likelihood of Approval
Luvixasertib is under clinical development by Treadwell Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
Luvixasertib by Treadwell Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval
Luvixasertib is under clinical development by Treadwell Therapeutics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
Luvixasertib by Treadwell Therapeutics for Sarcomas: Likelihood of Approval
Luvixasertib is under clinical development by Treadwell Therapeutics and currently in Phase II for Sarcomas. According to GlobalData, Phase II...
Luvixasertib by Treadwell Therapeutics for Endometrial Cancer: Likelihood of Approval
Luvixasertib is under clinical development by Treadwell Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Luvixasertib by Treadwell Therapeutics for Leiomyosarcoma: Likelihood of Approval
Luvixasertib is under clinical development by Treadwell Therapeutics and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II...